Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and Oncoinvent ASA, a clinical-stage radiopharmaceutical company, have entered into a strategic agreement for Thorium-228 radioisotopes to supply the Phase 3 clinical program for Radspherin®, Oncoinvent’s lead product candidate.

Oncoinvent reports continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing recruitment.

Oncoinvent will present operational and financial update for the first half of 2025 on Wednesday 27 August 2025 at 08:00am (CET). The presentation will be live streamed in English followed by a Q&A session.

Oslo, Norway, 4 August 2024 – Reference is made to the joint stock exchange announcement made on 30 June 2025 by Oncoinvent ASA (“Oncoinvent”) and BerGenBio ASA (“BerGenBio”) regarding the contemplated combination of the two companies through a statutory merger (the “Merger”). An extraordinary general meeting (the “EGM”) in Oncoinvent was held today at 12:00 hours (Oslo time). All proposals on the agenda were approved with the requisite majority, including the merger plan for the Merger dated 30 June 2025 (the “Merger Plan”).

An extraordinary general meeting in Oncoinvent ASA will be held on 4. August 2025 at 12:00 CEST. The meeting will be held in Gullhaugveien 7, Oslo with the possibility for a virtual participation. The formal call will be sent to all shareholders registered in the Norwegian Central Security Depository (VPS). The complete set of documents and link relating to the extraordinary general meeting will be made available on www.oncoinvent.com/investors/general-meetings.

Bergen, Norway and Oslo, Norway, 30 June 2025: BerGenBio ASA the (“Company”) hereby announces a fully underwritten rights issue with preferential subscription rights (the “Subscription Rights”) for the Company’s existing shareholders at the time of completion of the proposed merger between BerGenBio Norge AS, a wholly-owned subsidiary of the Company, and Oncoinvent ASA announced in a separate announcement earlier today (the “Merger”) to raise gross proceeds of approximately NOK 130 million, which pursuant to certain Underwriting Agreements (as defined below) will be fully underwritten by a consortium of underwriters comprising certain large shareholders in Oncoinvent ASA and certain external underwriters (the “Underwriters”) (the “Rights Issue”). The Rights Issue is subject to and will be completed subsequent to the completion of the Merger. The Merger is currently anticipated to be completed mid of September 2025 and the Rights Issue will then be implemented start/mid of October 2025.

Bergen, Norway and Oslo, Norway, 30 June 2025 – BerGenBio ASA (OSE: BGBIO) (“BerGenBio” or the “Company”) and Oncoinvent ASA (OSE: ONCIN) (“Oncoinvent”) announce that they have entered into a merger agreement (the “Agreement”) to combine the two companies through a statutory merger (the “Merger”), where BerGenBio will be the acquiring entity.

Oncoinvent ASA (OSE: ONCIN) a clinical stage radiopharmaceutical company developing innovative treatments for solid cancers, invites for a presentation of the top-line results from the Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases originating from colorectal cancer.

Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent’s novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer

Oslo, 14 May 2025: The annual general meeting of Oncoinvent ASA was held today, on 14 May 2025, as a digital meeting through Microsoft Teams. All proposals on the agenda were adopted in accordance with the board of directors’ proposals and the proposals from the nomination committee. The minutes of the annual general meeting are attached hereto and are also available on the company’s website www.oncoinvent.com/investors/general-meetings.